TKT and cancer: Therefore, TK inhibitors have become a promising therapeutic option for treatment of cancer types whose molecular pathogenesis implicates the overexpression or activation of various TKs (e.g., BCR/ABL) or TK receptors (e.g., c-KIT, PDGFR and EGFR, among others) [5].